Rare Disease

FDA Leadership Changes Spark Investor Return to Rare-Disease Biotech

Investors are reportedly re-entering rare-disease drug stocks after the departure of stricter FDA regulators under the Trump administration. The shift in agency leadership has reduced concerns about tougher approval hurdles that had previously discouraged investment in this biotech segment.